XML 31 R21.htm IDEA: XBRL DOCUMENT
v3.23.1

SEGMENT INFORMATION (Tables) | 6 Months Ended
--- | ---
Mar. 31, 2023
SEGMENT INFORMATION |
Schedule of information regarding operations by segment | Information regarding operations by segment for the three-month period ended March 31, 2023 is as follows:
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Therapeutic DNA | ​ | MDx Testing | ​ | DNA Tagging and | ​ |  | ​
​ |  | Production |  | Services |  | Security Products |  | Consolidated
Revenues: |  | ​ |  |  | ​ |  |  | ​ |  |  | ​ |
Product revenues | ​ | $ | 255,626 | ​ | $ | — | ​ | $ | 41,828 | ​ | $ | 297,454
Service revenues | ​ |  | 83,906 | ​ |  | — | ​ |  | 85,152 | ​ |  | 169,058
Clinical laboratory service revenues | ​ |  | — | ​ |  | 3,971,582 | ​ |  | — | ​ |  | 3,971,582
Less intersegment revenues | ​ |  | — | ​ |  | (30,480) | ​ |  | — | ​ |  | (30,480)
Total revenues | ​ | $ | 339,532 | ​ | $ | 3,941,102 | ​ | $ | 126,980 | ​ | $ | 4,407,614
Gross profit | ​ | $ | 215,477 | ​ | $ | 1,650,113 | ​ | $ | (58,155) | ​ | $ | 1,807,435
(Loss) income from segment operations (a) | ​ | $ | (1,054,123) | ​ | $ | 492,288 | ​ | $ | (914,736) | ​ | $ | (1,476,571)
​ Information regarding operations by segment for the three-month period ended March 31, 2022 is as follows:
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Therapeutic DNA | ​ | MDx Testing | ​ | DNA Tagging and | ​ |  | ​
​ |  | Production |  | Services |  | Security Products |  | Consolidated
Revenues: |  | ​ |  |  | ​ |  |  | ​ |  |  | ​ |
Product revenues | ​ | $ | — | ​ | $ | 180,023 | ​ | $ | 228,328 | ​ | $ | 408,351
Service revenues | ​ |  | 158,243 | ​ |  | — | ​ |  | 90,447 | ​ |  | 248,690
Clinical laboratory service revenues | ​ |  | — | ​ |  | 5,623,922 | ​ |  | — | ​ |  | 5,623,922
Less intersegment revenues | ​ |  | — | ​ |  | (133,680) | ​ |  | — | ​ |  | (133,680)
Total revenues | ​ | $ | 158,243 | ​ | $ | 5,670,265 | ​ | $ | 318,775 | ​ | $ | 6,147,283
Gross profit | ​ | $ | 158,243 | ​ | $ | 2,335,169 | ​ | $ | (4,927) | ​ | $ | 2,488,485
(Loss) income from segment operations (a) | ​ | $ | (1,049,207) | ​ | $ | 1,084,388 | ​ | $ | (1,292,632) | ​ | $ | (1,257,451)
​ Information regarding operations by segment for the six-month period ended March 31, 2023 is as follows: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Therapeutic DNA | ​ | MDx Testing | ​ | DNA Tagging and | ​ |  | ​
​ |  | Production |  | Services |  | Security Products |  | Consolidated
Revenues: |  | ​ |  |  | ​ |  |  | ​ |  |  | ​ |
Product revenues | ​ | $ | 383,132 | ​ | $ | — | ​ | $ | 430,718 | ​ | $ | 813,850
Service revenues | ​ |  | 205,649 | ​ |  | — | ​ |  | 195,470 | ​ |  | 401,119
Clinical laboratory service revenues | ​ |  | — | ​ |  | 8,537,397 | ​ |  | — | ​ |  | 8,537,397
Less intersegment revenues | ​ |  | — | ​ |  | (82,000) | ​ |  | — | ​ |  | (82,000)
Total revenues | ​ | $ | 588,781 | ​ | $ | 8,455,397 | ​ | $ | 626,188 | ​ | $ | 9,670,366
Gross profit | ​ | $ | 386,401 | ​ | $ | 3,583,332 | ​ | $ | 215,385 | ​ | $ | 4,185,118
(Loss) income from segment operations (a) | ​ | $ | (1,906,376) | ​ | $ | 1,602,172 | ​ | $ | (1,389,451) | ​ | $ | (1,693,655)
​ Information regarding operations by segment for the six-month period ended March 31, 2022 is as follows: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Therapeutic DNA | ​ | MDx Testing | ​ | DNA Tagging and | ​ |  | ​
​ |  | Production |  | Services |  | Security Products |  | Consolidated
Revenues: |  | ​ |  |  | ​ |  |  | ​ |  |  | ​ |
Product revenues | ​ | $ | — | ​ | $ | 522,844 | ​ | $ | 711,818 | ​ | $ | 1,234,662
Service revenues | ​ |  | 247,681 | ​ |  | — | ​ |  | 140,282 | ​ |  | 387,963
Clinical laboratory service revenues | ​ |  | — | ​ |  | 8,973,580 | ​ |  | — | ​ |  | 8,973,580
Less intersegment revenues | ​ |  | — | ​ |  | (283,216) | ​ |  | — | ​ |  | (283,216)
Total revenues | ​ | $ | 247,681 | ​ | $ | 9,213,208 | ​ | $ | 852,100 | ​ | $ | 10,312,989
Gross profit | ​ | $ | 247,681 | ​ | $ | 3,155,859 | ​ | $ | 194,083 | ​ | $ | 3,597,623
(Loss) income from segment operations (a) | ​ | $ | (1,973,984) | ​ | $ | 749,400 | ​ | $ | (2,189,032) | ​ | $ | (3,413,616)
​
Schedule of reconciliation of segment loss from operations to corporate loss | ​
​ | ​ | ​ | ​ | ​ | ​ | ​
Three-Month Period Ended: | ​ | March 31,
​ |  | 2023 |  | 2022
Loss from operations of reportable segments | ​ | $ | (1,476,571) | ​ | $ | (1,257,451)
General corporate expenses (b) | ​ |  | (1,227,453) | ​ |  | (896,785)
Interest income | ​ |  | 3,639 | ​ |  | 5,540
Unrealized gain on change in fair value of warrants classified as a liability | ​ |  | 3,250,900 | ​ |  | 782,500
Transaction cost allocated to warrant liabilities | ​ | ​ | — | ​ | ​ | (391,335)
Other income (expense), net | ​ |  | 661 | ​ |  | (2,266)
Consolidated income (loss) before provision for income taxes | ​ | $ | 551,176 | ​ | $ | (1,759,797)
​ ​
​ | ​ | ​ | ​ | ​ | ​ | ​
Six-Month Period Ended: | ​ | March 31,
​ |  | 2023 |  | 2022
Loss from operations of reportable segements | ​ | $ | (1,693,655) | ​ | $ | (3,413,616)
General corporate expenses (b) | ​ |  | (2,229,347) | ​ |  | (3,447,197)
Interest income | ​ |  | 7,325 | ​ |  | 5,813
Unrealized gain on change in fair value of warrants classified as a liability | ​ |  | 613,100 | ​ |  | 782,500
Transaction cost allocated to warrant liabilities | ​ | ​ | — | ​ | ​ | (391,335)
Other income (expense), net | ​ |  | 9,507 | ​ |  | (16,873)
Consolidated loss before provision for income taxes | ​ | $ | (3,293,070) | ​ | $ | (6,480,708)
​

X
- Definition Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599 + Details
Name: | us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration